Mucormycosis in patients with COVID-19 in Russia: the results of a prospective multi-center study

We present the results of a prospective multicenter study risk factors, etiology, clinical features, and treatment outcomes for mucormycosis in patients with COVID-19 (COVID-M) Russian Federation. The included 60 adult COVID-M. To analyze factors COVID-M, we conducted case-control study. control group without mucormycosis. manifestations created hematological examined 2011–2020. In COVID-19, developing was significantly increased diabetes mellitus (OR=49) overweight (OR=4,75), as well use high (≥100 mg per day prednisolone) doses glucocorticosteroids (OR= 4,762), especially ≥10 days (OR=25,4). main localization paranasal sinuses (95%) orbit (68%). Involvement ≥2 organs identified 70% patients. causative agents were Rhizopus arrhizus (43%) unidentified mucormycetes (36%). 90-days overall survival – 71%. stay ICU (p=0,01), mechanical ventilation (p=0,0481), presence CVC (p=0,049), CNS damage (p=0,016) ≥ 2 (p=0,048) worsened prognosis disease. best who received antifungal therapy (p=0,03875) surgical (p=0,046).